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Abstract
Background
Two contrasting approaches of a prophylactic gastrostomy or a nasogastric tube as needed are widely used to support patients receiving chemoradiotherapy for head and neck cancer. The influence of the type and timing of enteral feeding tube support upon long term swallowing is uncertain. This study analyses the patients' perspective on long term swallowing comparing two groups of patients who received chemoradiotherapy for oropharyngeal cancer managed with the two approaches.
Methods
The MD Anderson Dysphagia Inventory (MDADI) was posted to 63 consecutive patients with oropharyngeal squamous cell cancer treated with concurrent chemoradiotherapy between January 2007 and June 2009, who had not required therapeutic enteral feeding pre-treatment and who were disease free on follow up at least 2 years post-treatment.
Results
56
/63 patients completed questionnaires; 43 had been managed with a prophylactic gastrostomy and 13 with a policy of NG tube as needed. There were no significant differences in all global, emotional, physical or functional domains of the MDADI according to enteral feeding strategy. Diet at 6 months post-treatment was significantly correlated with better MDADI scores.
Conclusions
In this study the choice of a prophylactic gastrostomy or NG tube as needed did not appear to influence long term swallowing function.
Introduction
Concurrent chemo-radiotherapy is the preferred treatment strategy for organ preservation for locally advanced head and neck squamous cell carcinoma (HNSCC) . Trials have demonstrated a survival benefit for the addition of concurrent chemotherapy with the cost of increased treatment toxicity 1, 2 .
Acute treatment related side effects of odynophagia, dysphagia, xerostomia and mucositis with associated weight loss are common. A large majority of patients require oral or enteral nutritional supplementation during and after treatment. The proportion of patients reported as requiring enteral feeding varies between reported series, with between 50-100% of patients receiving chemoradiotherapy needing enteral nutritional support [3] [4] [5] . Risk factors for requiring enteral feeding include pre-treatment weight loss and dysphagia, older age, large primary tumours, and treatment related factors including the use of concurrent chemotherapy and radiation dose to the pharyngeal constrictors 6, 7 . Two main approaches have been used to provide enteral nutrional support: i) prophylactic tube placement prior to treatment, and ii) reactive tube placement if and when required. A gastrostomy tube is usually preferred for the former approach and a nasogastric (NG) tube for the latter 6 . A recent UK based survey revealed no consensus as to which patients should be offered a prophylactic gastrostomy 8 . This remains a contentious area, and both approaches to enteral feeding have advantages and drawbacks. Several studies have suggested that the use of prophylactic gastrostomy placement is associated with a reduction in weight loss during treatment, a lower rate of hospitalisation 4, [9] [10] [11] , and improved quality of life during and soon after treatment 12, 13 . Disadvantages of prophylactic gastrostomy placement prior to treatment include the possibility that the tube will not be required, a small risk of tube-related morbidity 14 , and the uncertain influence upon long term enteral feeding dependency rates 6, [9] [10] [11] 15 . . The use of concurrent chemoradiotherapy is associated with clinically significant rates of severe long term dysphagia 16, 17 . For example, an analysis of 3 RTOG studies found 13% of patients were gastrostomy-dependent 2 years post treatment 16 . Several studies have reported a significantly increased duration of enteral feeding with prophylactic gastrostomies compared with a reactive enteral feeding approach 9, 10, 15, 18 . This has led to concern that the use of prophylactic gastrostomy tubes may lead to poorer long term swallow function 6, 11, 19 . 
Methods
Study design
The study was registered with the Institutional Quality Improvement Board. In Table 1 . The 1 to 5 point scoring for each question is described in the legend for Table 1 . For each subscale (emotional, functional, physical) the scores are summed, and the mean score multiplied by 20 to provide a score with a range of 0-100 (with higher scores representing better functioning). The first question is scored individually in this manner to provide the global subscale. The MDADI questionnaire was sent a second time to non-responders after an interval of 2 months. 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 6 Data including oral intake (categorised as nil by mouth, sips, pureed diet, soft diet and normal diet), weight and the use of enteral feeding was routinely documented by the hospital dietetic team during treatment and during follow up by the local dietetic teams. Data (oral diet and enteral feeding) was collected by means of a proforma completed by the dietitians as previously described 10 . Data was requested at 6 weeks, 3, 6 and 12 months post radiotherapy in addition to the date of discontinuation of enteral feed.
Treatment details
Radiation therapy was delivered as previously described 21 using 6MV
photons with a 3D conformal technique. Target volume routinely included bilateral level 1b-V lymph nodes and retropharyngeal lymph nodes at least at the level of the oropharynx. Intensity modulated radiotherapy was not utilised during the study period. The standard radical dose was 70Gy in 35 fractions; adjuvant treatment for high risk patients was with 66Gy in 33 fractions.
Alternate dose fractionation schedules which were utilised are shown in Table   2 . Induction chemotherapy was utilised at clinician discretion. Docetaxel, cisplatin and 5-flurouracil (TPF) and cisplatin and 5-fluorouracil (PF) were used as previously described 21, 22 . Standard concurrent chemotherapy was cisplatin 100 mg/m 2 days 1 and 29. Carboplatin AUC 4 was substituted for cisplatin if creatinine clearance was <55ml/min. During chemoradiotherapy all patients were reviewed twice weekly by medical and nursing teams, and if required by dietitian and speech and language teams.
Statistical analysis
Statistical analysis was performed using STATA software version 10 (Statacorp, Texas, USA). Duration of enteral feeding was defined from last day of radiotherapy treatment. A t test and chi square tests were used as appropriate to test for differences in subgroups analysed. MDADI scores were compared using a non-parametric Mann Whitney U test. A univariate 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 Table 2 summarises the patient demographics and tumour details for the prophylactic gastrostomy and NG as needed groups. The only statistically significant imbalance between the groups was a slightly higher body mass index (BMI) in the NG as needed group. There was no difference recorded in pre-treatment diet between the two groups. Treatment details are shown in Table 3 .
Duration of enteral feeding
The median duration of enteral feeding post-radiotherapy was 161 days (95% CI 132-223) in the prophylactic gastrostomy group, and 53 days (95% CI 0-197) in the NG as needed group (p=0.68).
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Analysis of MDADI scores
The global and domain specific MDADI scores in both groups of patients, who were all at least 2 years post-treatment, are shown in Table 4 8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 10
Discussion
Enteral feeding is commonly required to maintain weight during and for a period of time after chemoradiotherapy treatment for HNSCC. Prophylactic feeding tube placement compared with a reactive approach has been reported in several studies to reduce the extent of treatment related weight loss and hospital admissions 4, 9, 10 , and to lead to improved short term quality of life 12, 13 . However, long term swallowing function is a major late toxicity associated with treatment, and should be a major factor in selecting the optimal strategy to support nutrition. 
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There is little other data available to assess long term swallowing function in relation to enteral feeding strategies at the time of treatment. Corry et al. 9 found a non-significant increase in grade 3 dysphagia 6 months posttreatment (25% versus 8%). Similarly, Mekhail et al. 15 compared 62 gastrostomy-fed patients with 29 NG tube-fed patients, finding 30% versus 8% dysphagia rates 6 months post-treatment. However, dysphagia was measured in these studies at a relatively early timepoint for the assessment of a late toxicity. Oozeer et al. 24 Many factors are likely to influence long term swallowing function following chemoradiotherapy 6, 7, 25 . These include patient and tumour factors, smoking status, radiation technique, maintenance of oral intake during treatment, adherence to swallowing exercise regimens, and swallowing rehabilitation support provided. The timing and type of feeding tube is another factor which is likely to have an influence. These multiplicity of factors make comparison between differing series and institutions complex. Our data suggests that the 13 use of a prophylactic gastrostomy does not inherently lead to poorer long term swallowing function. We do acknowledge the limitation of retrospective data of this type and further prospective work is need in this controversial area.
We consider it important that the use of any type of feeding tube is accompanied by an active programme to encourage early swallowing rehabilitation and discontinuation of enteral feeding; this support is required for a considerable period of time following completion of treatment. 
